IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes

PR70344

BRUSSELS, Sept. 29, 2017 /PRNewswire=KYODO JBN/ --

- Taking Diabetes to Heart is a global online survey for people with type 2

diabetes to gain important insights about their awareness of cardiovascular

disease (CVD)

- Globally, CVD is the most common cause of death in people with type 2

diabetes[1]

- Results from this survey will help the IDF and Novo Nordisk define actions

required to support public awareness of CVD among people with type 2 diabetes

to improve health outcomes

To mark World Heart Day today, the International Diabetes Federation (IDF) has

partnered with Novo Nordisk to launch the first-ever multi-country online

survey investigating the level of CVD awareness and knowledge among people

living with type 2 diabetes. The global survey - Taking Diabetes to Heart - is

available in multiple languages until March 2018, and people with type 2

diabetes are encouraged to participate.

Cardiovascular disease, which includes stroke, coronary heart disease and

peripheral artery disease,[2] is one of the leading causes of death in people

with type 2 diabetes,[1],[3] and as the number of people with diabetes

continues to increase,[4] the outlook for CVD becomes even more alarming.

"The world is facing rising prevalence and incidence of cardiovascular disease

among people with type 2 diabetes, due to limited knowledge on prevention, poor

access to timely diagnosis, inappropriate treatment and insufficiently informed

self-management. Taking Diabetes to Heart is a global effort to tackle the

underlying issues behind diabetes and cardiovascular diseases, their escalating

costs to societies, and to support cost-effective interventions that can help

reduce the current burden that they represent," said Dr Shaukat Sadikot, IDF

president.

Taking Diabetes to Heart - http://www.idf.org/takingdiabetes2heart/survey -

aims to define the actions that are required to support knowledge and awareness

of CVD among people living with type 2 diabetes to improve their health

outcomes. It builds on the IDF global report Diabetes and Cardiovascular

Disease, published in 2016, which includes a series of recommendations to

reduce the burden of CVD among people with diabetes and the general

population.[5]

"It is concerning that cardiovascular disease is the most common cause of death

in people with type 2 diabetes when many of these patients are unaware of this

risk," said Alan Moses, senior vice president and chief medical officer of Novo

Nordisk. "We are delighted to support the IDF in launching the survey, Taking

Diabetes to Heart, to better understand the current knowledge and awareness of

cardiovascular disease among people with type 2 diabetes, which will ultimately

inform actions needed to help improve health outcomes."

Taking Diabetes to Heart will culminate in a comprehensive report with

country-specific results and resources to help support knowledge and awareness

of CVD among people with type 2 diabetes around the world.

For more information about Taking Diabetes to Heart, visit

http://www.idf.org/takingdiabetes2heart

For more information about diabetes and CVD, visit http://www.idf.org/cvd

About the International Diabetes Federation

The International Diabetes Federation (IDF) is an umbrella organisation of over

230 national diabetes associations in 165 countries and territories. It

represents the interests of the growing number of people with diabetes and

those at risk. The Federation has been leading the global diabetes community

since 1950. The Federation's activities aim to influence policy, increase

public awareness and encourage health improvement, promote the exchange of

high-quality information about diabetes, and provide education for people with

diabetes and their healthcare providers. IDF is associated with the Department

of Public Information of the United Nations and is in official relations with

the World Health Organization (WHO). http://www.idf.org.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat other

serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in

77 countries and markets its products in more than 165 countries. For more

information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube  

About Taking Diabetes to Heart

Taking Diabetes to Heart - http://www.idf.org/takingdiabetes2heart - consists

of an online survey that will be available in multiple languages, including

Arabic, Chinese, Danish, Japanese, English, French, Spanish, Russian, Hindi,

Korean, Portuguese, German and Urdu. The survey will remain online until March

2018. Results from the survey will be used to inform policy and decision-making

around this common and serious complication of diabetes.[4]   

References

1. World Health Organization. Global health risks: mortality and burden of

disease attributable to selected major risks. Geneva, Switzerland: World Health

Organization; 2009.

2. Danaei G, Lawes CM, Vander Hoorn S, et al. Global and regional mortality

from ischaemic heart disease and stroke attributable to higher-than-optimum

blood glucose concentration: comparative risk assessment. The Lancet. 2006;

368:1651-1659. DOI: 10.1016/s0140-6736(06)69700-6.

3. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, et al. Type 2

diabetes and cardiovascular disease: Have all risk factors the same strength?

World J Diabetes. 2014; 5: 444-470. DOI: 10.4239/wjd.v5.i4.444.

4. International Diabetes Federation. IDF Diabetes Atlas, 7th Edition.

Brussels, Belgium: International Diabetes Federation, 2015. Available at:

http://www.diabetesatlas.org. Last accessed: September 2017.

5. International Diabetes Federation. Diabetes and Cardiovascular Disease.

Brussels, Belgium: International Diabetes Federation, 2016. Available at:

http://www.idf.org/cvd. Last accessed: September 2017.

Further information

Media :

Katrine Sperling

+45-4442-6718

krsp@novonordisk.com

Ken Inchausti (US)

+1-609-786-8316

kiau@novonordisk.com

Investors :

Peter Hugreffe Ankersen

+45-3075-9085

phak@novonordisk.com

Hanna Ögren

+45-3079-8519

haoe@novonordisk.com

Anders Mikkelsen

+45-3079-4461

armk@novonordisk.com

Christina Kjær

+45-3079-3009

cnje@novonordisk.com

Kasper Veje (US)

+1-609-235-8567

kpvj@novonordisk.com

IDF Media:

Lorenzo Piemonte

+32-2-5431-624

lorenzo.piemonte@idf.org

Suvi Karuranga

+32-2-6795-588

suvi.karuranga@idf.org

Source: Novo Nordisk